BERKELEY HEIGHTS, N.J., July 24, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today that it has entered into definitive agreements to raise $3.4 million in gross proceeds, before deducting placement agent fees and other estimated offering expenses, and up to an additional $2.5 million, in a registered direct offering with select institutional investors led by Special Situations Fund.
